Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group

James Z. Huang, Dennis D. Weisenburger, Julie Marie Vose, Timothy Charles Greiner, Patricia Aoun, Wing C. Chan, James C. Lynch, Philip Jay Bierman, James Olen Armitage

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We sought to investigate the clinical characteristics and pathologic features and survival outcome of patients with diffuse large B-cell lymphoma (DLBCL) arising in nodular lymphocyte predominant Hodgkin's disease (NLPHL), since controversy regarding their prognosis exists in the literature. Twenty-one patients with DLBCL arising either concurrently with (n = 7) or subsequent to (n = 14) a diagnosis of NLPHL were identified in the Nebraska Lymphoma Study Group Registry. The clinical and pathologic features of the cases were evaluated, and survival analysis was performed from the time of diagnosis of DLBCL. The median time to the development of DLBCL in those with prior NLPHL was only one year (range, 0.5-24 years). The median age of the patients at the time of diagnosis of DLBCL was 46 years (range, 18-72 years) and the male to female ratio was 17:4. Ten patients presented with nodal DLBCL only, six patients presented with both nodal and extranodal involvement, and five patients presented with only extranodal DLBCL. Eleven patients had limited stage (I/II) disease and 10 had advanced stage (III/IV) disease. The median overall survival (OS) and failure-free survival (FFS) of the entire group was 35 months and 11 months, respectively, and the predicted five-year OS and FFS was 31 and 18%, respectively. There were no significant differences in the survival outcomes between patients with DLBCL arising in NLPHL and age- and sex- matched patients with de novo DLBCL. In conclusion, our findings suggest that patients with DLBCL arising in NLPHL have a prognosis similar to those with de novo DLBCL and should be treated aggressively.

Original languageEnglish (US)
Pages (from-to)1903-1910
Number of pages8
JournalLeukemia and Lymphoma
Volume44
Issue number11
DOIs
StatePublished - Nov 1 2003

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease
Lymphoma
Survival
Survival Analysis
Registries
Lymphocytes

Keywords

  • Diffuse large B-cell lymphoma
  • Nodular lymphocyte predominant Hodgkin lymphoma
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group. / Huang, James Z.; Weisenburger, Dennis D.; Vose, Julie Marie; Greiner, Timothy Charles; Aoun, Patricia; Chan, Wing C.; Lynch, James C.; Bierman, Philip Jay; Armitage, James Olen.

In: Leukemia and Lymphoma, Vol. 44, No. 11, 01.11.2003, p. 1903-1910.

Research output: Contribution to journalArticle

@article{cd31b7692d9a4250bd5d6b783a3ae2c1,
title = "Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group",
abstract = "We sought to investigate the clinical characteristics and pathologic features and survival outcome of patients with diffuse large B-cell lymphoma (DLBCL) arising in nodular lymphocyte predominant Hodgkin's disease (NLPHL), since controversy regarding their prognosis exists in the literature. Twenty-one patients with DLBCL arising either concurrently with (n = 7) or subsequent to (n = 14) a diagnosis of NLPHL were identified in the Nebraska Lymphoma Study Group Registry. The clinical and pathologic features of the cases were evaluated, and survival analysis was performed from the time of diagnosis of DLBCL. The median time to the development of DLBCL in those with prior NLPHL was only one year (range, 0.5-24 years). The median age of the patients at the time of diagnosis of DLBCL was 46 years (range, 18-72 years) and the male to female ratio was 17:4. Ten patients presented with nodal DLBCL only, six patients presented with both nodal and extranodal involvement, and five patients presented with only extranodal DLBCL. Eleven patients had limited stage (I/II) disease and 10 had advanced stage (III/IV) disease. The median overall survival (OS) and failure-free survival (FFS) of the entire group was 35 months and 11 months, respectively, and the predicted five-year OS and FFS was 31 and 18{\%}, respectively. There were no significant differences in the survival outcomes between patients with DLBCL arising in NLPHL and age- and sex- matched patients with de novo DLBCL. In conclusion, our findings suggest that patients with DLBCL arising in NLPHL have a prognosis similar to those with de novo DLBCL and should be treated aggressively.",
keywords = "Diffuse large B-cell lymphoma, Nodular lymphocyte predominant Hodgkin lymphoma, Non-Hodgkin's lymphoma",
author = "Huang, {James Z.} and Weisenburger, {Dennis D.} and Vose, {Julie Marie} and Greiner, {Timothy Charles} and Patricia Aoun and Chan, {Wing C.} and Lynch, {James C.} and Bierman, {Philip Jay} and Armitage, {James Olen}",
year = "2003",
month = "11",
day = "1",
doi = "10.1080/1042819031000123528",
language = "English (US)",
volume = "44",
pages = "1903--1910",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group

AU - Huang, James Z.

AU - Weisenburger, Dennis D.

AU - Vose, Julie Marie

AU - Greiner, Timothy Charles

AU - Aoun, Patricia

AU - Chan, Wing C.

AU - Lynch, James C.

AU - Bierman, Philip Jay

AU - Armitage, James Olen

PY - 2003/11/1

Y1 - 2003/11/1

N2 - We sought to investigate the clinical characteristics and pathologic features and survival outcome of patients with diffuse large B-cell lymphoma (DLBCL) arising in nodular lymphocyte predominant Hodgkin's disease (NLPHL), since controversy regarding their prognosis exists in the literature. Twenty-one patients with DLBCL arising either concurrently with (n = 7) or subsequent to (n = 14) a diagnosis of NLPHL were identified in the Nebraska Lymphoma Study Group Registry. The clinical and pathologic features of the cases were evaluated, and survival analysis was performed from the time of diagnosis of DLBCL. The median time to the development of DLBCL in those with prior NLPHL was only one year (range, 0.5-24 years). The median age of the patients at the time of diagnosis of DLBCL was 46 years (range, 18-72 years) and the male to female ratio was 17:4. Ten patients presented with nodal DLBCL only, six patients presented with both nodal and extranodal involvement, and five patients presented with only extranodal DLBCL. Eleven patients had limited stage (I/II) disease and 10 had advanced stage (III/IV) disease. The median overall survival (OS) and failure-free survival (FFS) of the entire group was 35 months and 11 months, respectively, and the predicted five-year OS and FFS was 31 and 18%, respectively. There were no significant differences in the survival outcomes between patients with DLBCL arising in NLPHL and age- and sex- matched patients with de novo DLBCL. In conclusion, our findings suggest that patients with DLBCL arising in NLPHL have a prognosis similar to those with de novo DLBCL and should be treated aggressively.

AB - We sought to investigate the clinical characteristics and pathologic features and survival outcome of patients with diffuse large B-cell lymphoma (DLBCL) arising in nodular lymphocyte predominant Hodgkin's disease (NLPHL), since controversy regarding their prognosis exists in the literature. Twenty-one patients with DLBCL arising either concurrently with (n = 7) or subsequent to (n = 14) a diagnosis of NLPHL were identified in the Nebraska Lymphoma Study Group Registry. The clinical and pathologic features of the cases were evaluated, and survival analysis was performed from the time of diagnosis of DLBCL. The median time to the development of DLBCL in those with prior NLPHL was only one year (range, 0.5-24 years). The median age of the patients at the time of diagnosis of DLBCL was 46 years (range, 18-72 years) and the male to female ratio was 17:4. Ten patients presented with nodal DLBCL only, six patients presented with both nodal and extranodal involvement, and five patients presented with only extranodal DLBCL. Eleven patients had limited stage (I/II) disease and 10 had advanced stage (III/IV) disease. The median overall survival (OS) and failure-free survival (FFS) of the entire group was 35 months and 11 months, respectively, and the predicted five-year OS and FFS was 31 and 18%, respectively. There were no significant differences in the survival outcomes between patients with DLBCL arising in NLPHL and age- and sex- matched patients with de novo DLBCL. In conclusion, our findings suggest that patients with DLBCL arising in NLPHL have a prognosis similar to those with de novo DLBCL and should be treated aggressively.

KW - Diffuse large B-cell lymphoma

KW - Nodular lymphocyte predominant Hodgkin lymphoma

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0242467357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242467357&partnerID=8YFLogxK

U2 - 10.1080/1042819031000123528

DO - 10.1080/1042819031000123528

M3 - Article

VL - 44

SP - 1903

EP - 1910

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -